Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

May 15, 2023

Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month

May 2, 2023

Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

April 10, 2023

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

April 3, 2023

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

March 23, 2023

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

March 21, 2023

Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery

March 14, 2023

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 28, 2023

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 23, 2023

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

February 22, 2023

‹
1
…
7
8
9
10
11
…
16
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.